Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first quarter of 2024. Despite expectations that its top-selling interleukin blocker Dupixent (dupilumab) will face challenges from a co-pay assistance program in the first quarter, the company projects that the drug’s sales will reach EUR 13 billion (USD 14.1 billion) this year, up from EUR 10.7 billion (USD 11.6 billion) in 2023.
The multiple sclerosis (MS) drug Aubagio (teriflunomide) is anticipated to face generic competition following the loss of its patent in Europe and the US last year. Similarly, the stem cell mobilizer Mozobil (plerixafor) is expected to encounter generic erosion in Europe in 2024. Furthermore, profits from the antidiabetic Lantus (insulin glargine) will reflect a significant 78% reduction in list price in the US.
The guidance highlights the China market, which contributed significantly to Toujeo (insulin glargine) sales in Q4 2023 after the product overtook Lantus’s market share. However, the performance of the deep-vein thrombosis prophylactic Lovenox (enoxaparin) was affected in other regions due to the VBP (volume-based procurement) mechanism.- Flcube.com
